ANNX Tiesioginiai signalai | Didinkite pelną su Getagraph.com

PIRKIMAS 139609 min ago

@ $5.26

Išleistas: 14 vas. 2024 @ 21:48

Grąža: -10.75%

Ankstesnis signalas: vas. 14 - 16:31

Ankstesnis signalas: Pardavimas

Grąža: 2.24 %

Live Chart Being Loaded With Signals

Commentary (21 geg. 2024 @ 21:34):

Annexon, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapeutics for autoimmune, neurodegenerative, and ophthalmic disorders...

Stats
Šios dienos apimtis	517 673
Vidutinė apimtis	1.93M
Rinkos kapitalizacija	427.45M
EPS	$0 ( 2024-05-13 )
Kita pelno data	( $-0.250 ) 2024-08-05
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-3.21
ATR14	$0.00800 (0.17%)

Insider Trading

Date	Person	Action	Amount	type
2024-05-01	Carson William H.	Buy	3 200	Common Stock
2024-04-08	Carson William H.	Buy	3 200	Common Stock
2024-02-16	Love Douglas	Buy	656 200	Stock Option (Right to Buy)
2024-02-16	Dananberg Jamie	Buy	160 000	Stock Option (Right to Buy)
2024-02-16	Dananberg Jamie	Buy	39 000	Common Stock

INSIDER POWER
80.76
Last 94 transactions
Buy: 9 091 580 \| Sell: 849 119

Tūris Koreliacija

Ilgas: -0.12 (neutral)

Trumpas: 0.99 (very strong)

Signal:(58.054) Expect same movement, but be aware

Annexon, Inc. Koreliacija

10 Labiausiai teigiamai susiję koreliacijos
HNST	0.825
VINC	0.809

10 Labiausiai neigiamai susiję koreliacijos

Ar žinojote?

Koreliacija yra statistinis rodiklis, aprašantis ryšį tarp dviejų kintamųjų. Jis svyruoja nuo -1 iki 1, kur -1 reiškia tobulo neigiamo ryšio koreliaciją (padidėjus vienam kintamajam, sumažėja kitas), 1 reiškia tobulo teigiamo ryšio koreliaciją (padidėjus vienam kintamajam, padidėja ir kitas), o 0 reiškia jokios koreliacijos (tarp kintamųjų nėra jokio ryšio).

Koreliacija gali būti naudojama analizuojant bet kurių dviejų kintamųjų ryšį, ne tik akcijų. Jis dažnai naudojamas finansų, ekonomikos, psichologijos ir kitose srityse.

Annexon, Inc. Koreliacija - Valiuta/Žaliavos

0.51
( weak )

0.34
( neutral )

0.00
( neutral )

0.76
( moderate )

-0.50
( weak negative )

0.40
( neutral )

Annexon, Inc. Finansinės ataskaitos

Annual	2023
Pajamos:	$0
Bruto pelnas:	$-3.27M (0.00 %)
EPS:	$-1.770

FY	2023
Pajamos:	$0
Bruto pelnas:	$-3.27M (0.00 %)
EPS:	$-1.770

FY	2022
Pajamos:	$0
Bruto pelnas:	$-3.31M (0.00 %)
EPS:	$-2.53

FY	2021
Pajamos:	$0.00
Bruto pelnas:	$0.00 (0.00 %)
EPS:	$-7.68

Financial Reports:

No articles found.

Annexon, Inc. Options Data

Calls

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Puts

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Annexon, Inc.

Annexon, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapeutics for autoimmune, neurodegenerative, and ophthalmic disorders. The company's C1q is an initiating molecule of the classical complement pathway that targets distinct disease processes, such as antibody-mediated autoimmune disease and complement-mediated neurodegeneration. Its product candidates include ANX005, a monoclonal antibody, which is in Phase II/III clinical trials to treat patients with guillain- barré syndrome; Phase II trial in patients with warm autoimmune hemolytic anemia; and Phase II clinical trial for Huntington's disease and amyotrophic lateral sclerosis. The company is also developing ANX009 that is in Phase Ib trial in patients with lupus nephritis; and ANX007, which is in Phase II clinical trials to treat patients with geographic atrophy. In addition, it develops ANX105, an investigational monoclonal antibody targeting neurodegenerative indications; and ANX1502, an investigational oral small molecule for the treatment of certain autoimmune indications. The company was incorporated in 2011 and is headquartered in Brisbane, California.